Chapter

6. Bexlutry for Neuroendocrine Tumors

From 10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE by 10 Cancer Treatment Approvals From September 2026 and What They Mean for You

Concepts

  1. Bexlutry Approval

    "Approved: Sept. 14\n\nBexlutry is a new version of lutetium Lu 177 dotatate, a radiation-delivering treatment for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs

  2. Treatment Access

    "What it means for you: A second source of this treatment could help with supply and access. The treatment itself is the same type of radioligand therapy many people with GEP-NETs already receive."

6. Bexlutry for Neuroendocrine Tumors | 10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE | Bifalgorithm | Bifalgorithm